Leerink Partnrs Issues Pessimistic Outlook for VIRX Earnings

Viracta Therapeutics, Inc. (NASDAQ:VIRX) – Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of Viracta Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.80) for the year, down from their previous forecast of ($0.69). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Viracta Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.40) EPS.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada decreased their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Thursday. Leerink Partners cut shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $5.00 to $3.00 in a research report on Friday, August 16th.

Viracta Therapeutics Stock Down 4.4 %

Shares of NASDAQ VIRX opened at $0.15 on Monday. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31. The company has a market cap of $6.00 million, a price-to-earnings ratio of -0.14 and a beta of 0.72. The business has a fifty day simple moving average of $0.22 and a 200-day simple moving average of $0.43.

Institutional Trading of Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC purchased a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned approximately 1.27% of Viracta Therapeutics as of its most recent filing with the SEC. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.